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Previously, we reported that minocycline, kanamycin and norﬂoxacin improved the survival rate in the
E32511 model that we developed (FEMS Immunol Med Microbiol 26, 101–108, 1999), but fosfomycin did
not. In this study, we investigated the effectiveness of azithromycin (AZM) against Stx2d-producing EHEC
O91:H21 strain B2F1 or Stx2c-producing Escherichia coli strain E32511 treated with mitomycin C in vivo.
Recently,we reported the effectiveness of AZM inourmodel andAZMstrongly inhibited the release of Stx2c
from E32511 in vitro (PLOS ONE e58959, 2013). However, it was very difﬁcult to completely eliminate
E32511 in the mouse feces by treatment with AZM alone. In this report, only AZM or Daio effectively
promoted survival ofmice infectedwithB2F1 compared tountreatedmice. Furthermore, Daio inhibited the
colonizationofGFP-expressingB2F1 in themouse intestine. Similarly, a combinationofAZMandDaio in the
E32511-infected mice reduced E32511 in the mouse feces and signiﬁcantly improved survival.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
A large outbreak of Shiga toxin (Stx)-producing enter-
oaggregative Escherichia coli (EAEC) O104:H4 occurred in northern
Germany. Of the outbreak, at least 810 developed hemolytic uremic
syndrome (HUS), resulting in more than 54 deaths in 2011 [1,2].
30% of HUS patients showed encephalopathy. In Japan, an outbreak
of enterohemorrhagic Escherichia coli (EHEC) O111 infection
occurred in 2011. A total of 181 people suffered from diarrhea, and
surprisingly, encephalopathy developed in 21 (62%) of the HUS
patients [3]. Central nervous system (CNS) dysfunction is an
important predictive factor for HUS and mortality. Previously, we
developed a mouse model of CNS disorders by oral infection with
the Stx2c-producing EHEC O157: H, resulting in damage to the
endothelial cells of capillaries and to nerve ﬁbers in the cerebral
cortex and spinal cord of the infected mice [4].
All members of the Stx family are comprised of 1A and 5B
subunit proteins [5]. The A subunit is an N-glycosidase, thati).
All rights reserved.removes adenine from nucleotide No. 4324 of 28S RNA of the 60S
ribosomal subunit [6]. Stx produced by Shigella dysenteriae is
identical to Stx1 [7]. The amino acid sequence identity between the
A subunits of Stx1 and Stx2 has been reported to be only 55% [8].
Each B subunit of Stx1 and Stx2 has a high afﬁnity to the glyco-
sphingolipid globotriaosylceramide (Gb3 or CD77), which is pre-
sent in some eukaryotic cells [9].
In 1996, a large outbreak of E. coli O157:H7 infection occurred
among schoolchildren in Sakai City, Osaka, Japan. 9492 patients
suffered from diarrhea and hemorrhagic colitis, 121 patients
developed HUS, and 3 children died. After the outbreak in Japan, the
treatment guidelines for EHEC infectionwere made by the Ministry
of Public Welfare. The administration of antimicrobial agents, fos-
fomycin (FOM), kanamycin (KM) and norﬂoxacin (NFLX) was rec-
ommended in the said guidelines. Also, Ikeda K et al. reported that
FOM was the most frequently administered, and that its adminis-
tration within 3 days of illness reduced the risk of HUS [10]. We
previously reported the therapeutic effects of the antimicrobial
agents FOM, minocycline (MINO), KM and NFLX in our EHEC
O157:H (strain E32511/HSC) infected mouse model [11]. Results
showed that MINO, KM and NFLX were signiﬁcantly effective but
FOM was not [11]. Zhang et al. reported that gnotobiotic piglets,
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the Stx1- and Stx2-producing EHECO157:H7 strain 933W,were able
to survive and had little or no brain hemorrhage compared with a
ciproﬂoxacin (CPFX)-treated group [12]. Recently, we also reported
the effectiveness of azithromycin (AZM) in our model, and AZM
strongly inhibited the release of Stx2c from E32511 in vitro [13].
Similarly, we conﬁrmed the effectiveness of AZM in our E32511
model with oral inoculation of E32511 [13]. We also used a strep-
tomycin (SM)-treated mouse model of infection with the highly
virulent Stx2d-producing EHEC O91:H21 strain B2F1 (B2F1 model,
see methods). The 50% lethal dose (LD50) of the SM-resistant strain
B2F1, when fed to SM-treated mice, was less than 10 bacteria [14].
In the current study, we developed a new treatment combining
AZM and the Chinese medicine Daio. Daio is a traditional medicine
from China frequently used for the treatment of constipation,
inﬂammation and cancer [15]. Daio has active substances, such as
anthranoids and anthraquinone glycosides, which have laxative
and purgative effects, thus is able to increase the movement of the
intestine [16,17]. Through this mechanism, we hypothesize that
Daio will accelerate the shedding of bacteria, including the toxin, in
the feces.
2. Materials and methods
2.1. Ethics statement
Animal experiments were carried out in strict accordance with
the recommendations in Guidelines for Proper Conduct of Animal
Experiments of Science Council of Japan. The protocol was
approved by the Committee on the Ethics of Animal Experiments of
Kyushu University, Japan (Permit Number: A23-141-1). All surgical
procedures were performed under sevoﬂurane anesthesia, and all
efforts were made to minimize suffering.
2.2. Bacterial strains
The Stx2c-producing E. coli O157:H strain E32511/HSC was
used in this study [4]. The Stx2d-producing E. coli O91:H21 strain
B2F1 was isolated from a human [18] and was a gift from Professor
Alison O’Brien (Uniformed Services University of the Health Sci-
ences, USA). Streptomycin (SM)- and mitomycin C (MMC)-resistant
E32511/HSC were grown in nutrient agar supplemented with
100 mg/mL of SM (Wako Pure Chemical Industries, Ltd., Osaka,
Japan), 0.5 mg/mL of MMC (Kyowa Hakko Kogyo Co., Ltd., Tokyo,
Japan). SM-resistant B2F1 was prepared as above. E. coli K-12,
which is resistant to SM and MMC, was used as a negative control.
E32511/HSC, B2F1 and E. coli K-12were grownwith shaking for 17 h
in LuriaeBertani broth (LB broth) at 37 C. The bacterial pellets
were then harvested by centrifugation at 6000 g for 25min at 4 C
before being washed twice with phosphate-buffer saline (PBS) by
centrifugation (6000 g for 20min at 4 C). Finally, bacterial pellets
were suspended in PBS and the appropriate number of CFUs was
given orally to the mice.
E. coli O91:H21 strain B2F1 expressing pGFP was prepared as
follows. The pGFPuv vector (100 ng; BD Biosciences, San Jose, CA,
USA) was transformed into the competent E. coli O91:H21 strain
B2F1. Competent cells were prepared using rubidium chloride as
previously described [19]. Reactions were plated on an L-agar plate
containing ampicillin (100 mg/mL), and transformed colonies were
identiﬁed by ﬂuorescence when exposed to UV light.
2.3. Animals
Four week-old female ICR outbred mice purchased from Japan
SLC, Inc. (Shizuoka, Japan) were used for all in vivo experiments inthis study. They were housed in cages with a 12 h lightedark cycle
and free access to laboratory food and distilled water.
2.4. B2F1 model
We used previously developed SM-resistant B2F1 and GFP-B2F1
bacteria as B2F1 and GFP-B2F1 models [14]. The mice were given
SM-containing drinking water (5 g/L) ad libitum. On day 3 of SM
treatment, mice were completely deprived of food for 12 h prior to
bacterial inoculation. The mice were infected with 0.5 mL of bac-
terial suspension containing 102 CFU of B2F1 or 104 CFU of GFP-
B2F1, the dose required in order to cause 100% death in mice, us-
ing a sterile disposable feeding needle passed into the stomach by
orogastric inoculation. In this model, the following neurological
signs and symptoms were observed: weight loss, ﬂaccid paralysis,
and tremor culminating in death within 6e12 days after infection.
2.5. E32511 model
For the in vivo experiments, the mice were divided into groups
of 5 or 6. In this study, as our late stage mouse model, we used a
mouse model orally infected with E32511/HSC and i.p. injected
with MMC [4]. Brieﬂy, all mice were given SM-containing drinking
water (5 g/L) ad libitum to reduce the level of their normal intestinal
ﬂora [20]. On day 3 of SM treatment, all the mice were completely
deprived of food for 12 h until bacterial inoculation. Each mouse
was infected with 0.5 mL of bacterial suspension using a sterile
disposable feeding needle (diameter, 1.9 mm; length, 38 mm,
Fuchigami Co., Ltd., Nara, Japan) attached to a syringe passed into
the stomach by orogastric inoculation. Subsequently, they were
injected i.p. with 2.5 mg/g MMC. We reported that 90% of the mice
infected with 5  1010 CFU of E32511 orally plus i.p. injection of
MMC developed weight loss, ﬂaccid paralysis and tremor, culmi-
nating in death [4]. In this study, the bacterial suspension of E32511
was adjusted to 1  1011 CFU in PBS and caused 100% death. After
the completion of treatment, they were housed according to the
treatment groups and given food and SM-containing drinking
water (5 g/L) ad libitum. The mice were observed twice daily for 2
weeks, for survival and/or signs of illness. We collected the mouse
feces, plated, and counted the total bacterial load. Log-rank and c2
tests were used to evaluate the survival rate of the different treat-
ment groups. Statistical signiﬁcance was set at p < 0.05.
2.6. In vivo colonization of GFP-expressing B2F1 in the mouse colon
tract
The colonization sites of SM-resistant-GFP-expressing B2F1
(GFP-B2F1) in the intestinal tract were evaluated in the SM-treated
mouse model. Four-week-old female ICR mice were divided into
three groups. The mice were given SM-containing drinking water
(5 g/L) ad libitum to reduce the level of their normal intestinal ﬂora.
On day 3 of SM treatment, all the mice were completely deprived of
food for 12 h until bacterial inoculation. Each group was infected
with 0.5 mL of bacterial suspension using a sterile disposable
feeding needle. 104 CFU of GFP-B2F1 were administered orally, and
PBS was orally administered as a negative control. The treatment
group was treated with 300 mg/g Daio in distilled water once a day
for 5 days starting from the day after inoculation with GFP-B2F1.
The Daio-treated group consisted of seven mice, and three mice
were used as negative controls. Eight and 10 after treatment, three
mice from each group were sacriﬁced to observe the colonization
by GFP-B2F1. Mice were sacriﬁced after being anesthetized with an
i.p. injection of amixture of 2,2,2-tribromoethanol and 2-methyl-2-
butanol, after which the colonwas excised and cut into 1 cm pieces.
Before cutting, the colon was washed to remove fecal material by
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cut in the longitudinal plane and put into 35mm glass-based dishes
(Iwaki & Co., Ltd., Tokyo, Japan), upside down. Immediately, the
images of colonmucosa layer were captured with a Keyence HS All-
in-one Fluorescence Microscope BZ-9000E, with 20 magniﬁca-
tion. GFP expression was analyzed using BZ-II Analyzer BZ-H2AE/
BZ-HIME/BZ-H1RE/BZ-H2TLE/BZ-H1CE software (Keyence). Simul-
taneously, bacterial counting was done by homogenizing the colon
and the ileum in PBS using a Multi Bead Shocker (Yasui Kikai Corp.,
Osaka, Japan), followed by serial dilution and plating on L-agar
plates containing 100 mg/mL of SM, and the number of CFU/mouse
colon and ileum were counted. The strain of selected colonies was
conﬁrmed by slide-agglutination with anti-O91 serum (Denka
Seiken Co., Ltd, Tokyo, Japan).
2.7. Statistical analysis
Data were analyzed with SPSS Statistics 19.0 (IBM Japan, Tokyo,
Japan) and Delta Graph 6vJ Win (Red Rock Software, Inc. Salt Lake
City, UT, USA) was used to draw the graphs. The signiﬁcance of the
survival rate from each treatment group was compared using a
KaplaneMeier test followed by a pair-wise comparison of Log Rank
(ManteleCox) test, and Student’s t-test was used to show the sig-
niﬁcant values between negative control, positive control and treat-
ment groups. Signiﬁcance was set at a value of p < 0.05 in all cases.
3. Results
3.1. The effects of AZM or Daio in the B2F1 model
We investigated the effectiveness of treatment with AZM or
Daio alone using the B2F1 model. To cause death in 100% of mice
infected with B2F1, WT B2F1 bacteria and GFP-expressing B2F1
bacteria required a dose of 102 CFU and 104 CFU, respectively. AZM
was given orally at a dose of 25 mg/g at 24 h after infection as a
single dose or once a day for three days in the B2F1model. Themice
treated with these doses showed signiﬁcantly improved survival
compared to the untreated mice (p < 0.01) (Fig. 1A).
Next, we investigated the effectiveness of Daio in the GFP-B2F1
model only. In in vitro experiments, Daio had no antibacterial ac-
tivity against either the B2F1 or the GFP-B2F1 strains (data not
shown). Daio administered at a concentration of 300 mg/g at 24 h
after infection once a day for 5 consecutive days was found to
signiﬁcantly enhance the survival of treated mice compared with
those to which the same concentration of Daio was administered
once a day for 3 days or with the untreated group (Fig. 1B).Fig. 1. Effects of AZM or Daio in the B2F1 model. (A) 25 mg/g AZM, once a day for 3 conse
signiﬁcant effect on survival (AZM 25 mg/g single dose vs. untreated, p ¼ 0.001; AZM 25 mg/g
5 consecutive days after infection was signiﬁcantly more effective than no treatment (Daio 5
was not effective compared to untreated; (Daio 3 days vs. untreated, p > 0.05). *p < 0.05.3.2. In vivo colonization of GFP-expressing B2F1 in the mouse colon
tract
To conﬁrm the effectiveness of Daio, we counted the number of
GFP-B2F1 cells in the tissues of the mouse colon and ileum. One day
after infection with GFP-B2F1, mice were treated with 300 mg/g
Daio once a day for 5 consecutive days. The mice were sacriﬁced
and the bacteria were harvested from the tissues of the colon and
the ileum at days 5, 8 and 10 after treatment. After washing the
feces out, the intestines were homogenized and GFP-B2F1 cells
were enumerated. Results showed that there was a signiﬁcant
decrease in the number of GFP-B2F1 in the tissues of the colon and
the ileum of infectedmice at days 8 and 10 after treatment (Fig. 2A).
To conﬁrm the colonization of the colon by the GFP-B2F1 strain, the
mice infected with GFP-B2F1 were sacriﬁced and the colon tissue
was washed with PBS to remove the feces without attempting to
remove the bacteria that adhered to the mucosa of the colon. The
colon was then observed using ﬂuorescence and light microscopy.
The mucosal epithelium of the colon of the mice treated with Daio
and that of the untreated mice were observed under a ﬂuorescence
microscope. In the Daio-treated group, no GFP-B2F1 was observed
on day 10 (Fig. 2B; Daio-treated, day 10, down), whereas many GFP-
B2F1 were observed in the untreated group at day 10 (Fig. 2B;
untreated, day 10, down). On day 8, the colonization by B2F1 of the
Daio-treated mouse colon was almost the same as that of the un-
treated mouse colon (Fig. 2B; untreated and Daio-treated, day 8,
down). Furthermore, under the light microscope, the shape of the
mucosal epithelium of the colon of Daio-treated mice was regular
on day 10 after treatment (Fig. 2B; Daio-treated, up). In the un-
treated group, the mucosal epithelium of the colon was irregularly
shaped on day 10 (Fig. 2B; untreated, day 10, up). Based on our
results, we conclude that a single dose of 25 mg of AZM and 300 mg/g
Daio are effective in treating B2F1-infected mice.
3.3. Effects of AZM combined with Daio in the E32511 model
Then, we determined the extent of the effectiveness of AZM by
combining it with Daio in the E32511 model. Before the combina-
tion treatment, we conﬁrmed whether Daio alone was effective in
the E32511 model. Treatment with Daio (300 mg/g) alone, once or
twice, was not effective in this model (Table 1, Nos. 2e5). Addi-
tionally, treating mice with AZM (200 mg/g) 6 h after inoculation of
E3211 was not effective (Table 1, No. 6). We administered a com-
bination of AZM (200 mg/g) 6 h after infection with Daio 300 mg/g
once 2 h after infection, and it was not effective in this mouse
model (Table 1, No. 7). Subsequently, we tested a combination ofcutive days after infection were signiﬁcantly more effective than no treatment, with a
3 consecutive days vs. untreated, p ¼ 0.001). *p < 0.05. (B) 300 mg/g Daio, once a day for
days vs. untreated, p ¼ 0.018), while 300 mg/g Daio, once a day for 3 days after infection
Fig. 2. In vivo colonization of GFP-expressing B2F1 in the mouse colon tract. (A) The number of bacteria on days 8 and 10 after infection was signiﬁcantly decreased in the colon of
GFP-B2F1-infected mice by administration of 300 mg/g Daio once a day for 5 consecutive days (day 8 bacteria in colon of Daio vs. untreated, p ¼ 0.020; day 10 bacteria in colon of
Daio vs. untreated, p < 0.0001) and in the small intestine of GFP-B2F1-infected mice on days 8 and 10 after infection after the administration of 300 mg/g Daio once a day for 5
consecutive days (day 8 bacteria in the small intestine of Daio vs. untreated, p ¼ 0.010; day 10 bacteria in the small intestine of Daio vs. untreated, p < 0.0001). Student’s t test,
*p < 0.05; **p < 0.001. (B) GFP-B2F1 colonization in the mouse colon. An increase in green spot distribution (representing colonization by bacteria) was observed in the untreated
group compared with the Daio-treated group at days 8 and 10 after treatment. (Scale bars ¼ 50 mm). Data were collected from at least 3 out of the 7 mice per day, from two
independent experiments for each treatment group.
Table 1
Effect of Daio, AZM and combination treatment of AZM and Daio on the lethality of
the E32511 model.
No. of
experimental
design
Treatment of
Daio and/
or AZM
Time line after infection No. of death/
experimental
total no.
2 h 6 h 24 h
1 No treatment 5/5
2 Daio once Daio 5/5
3 Daio once Daio 5/5
4 Daio once Daio 5/5
5. Daio twice Daio Daio 5/5
6 AZM once AZM 3/5
7 Combination
of AZM and Daio
Daio AZM 3/5
8 Combination of
AZM and Daio
Daio AZM Daio 1/5*
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g) twice, 2 h and 24 h after infection. This was signiﬁcantly effective
(Table 1, No. 8). This combination of AZM and a double dose of Daio
improved the survival period compared with the group treated
with the combination of AZM and a single dose of Daio (Fig. 3A).
Furthermore, the bacterial count in the feces signiﬁcantly
decreased compared with that of the mice treated with AZM alone
(Fig. 3B). We were, therefore, able to develop a new treatment,
comprising of a combination of AZM and Daio, which is effective in
the E32511 model.4. Discussion
In this study we report four signiﬁcant results. 1) The macrolide
antibiotic AZM or Daio was strongly effective in the B2F1 model. 2)
In the GFP-B2F1 model, treatment with the Chinese medicine Daio
alone was found to inhibit the colonization by GFP-B2F1 in themouse intestine. 3) We developed a new therapy using a combi-
nation of AZM and Daio in the E32511 model. Because it was very
difﬁcult to completely eliminate gram-negative bacteria, such as
E. coli E32511, in the mouse feces by treatment with AZM alone, we
were able to show that a combination of AZM and Daio reduced
E32511 in the mouse feces.
Recently, Zhang et al. reported that a pediatric dose (10 mg/kg) of
AZM was effective in the piglet model orally infected with Stx2-
producing E. coli, and that recA mutants treated with the phage-
inducing agent MMC and a sub-inhibitory concentration of CPFX
failed to produce Stx2 [12]. We also previously reported that MINO,
KM and NFLX improved the survival rate in our E32511 model, but
FOM did not [11]. Other antimicrobial agents induced the produc-
tion of Stx2c including FOM, NLFX, KM, oﬂoxacin (OFLX), and cip-
roﬂoxacin (CPFX) by 1.5-, 12.5-, 2.25-, 12.5- and 100-fold over
control, respectively [13].
In this report, the treatment with the Chinese medicine Daio
alone was found to be effective in the GFP-B2F1 model. It was very
difﬁcult to completely eliminate gram-negative bacteria, such as
E. coli E32511, in the mouse feces by treatment with AZM alone. We
developed a new therapy using a combination of AZM and Daio in
the E32511 model. The combination of AZM and Daio reduced
E32511 in the mouse feces.
To determine the extent of the effectiveness of AZM, we used a
Chinese medicine, Daio. Oi et al. reported that several puriﬁed
components of Daio effectively inhibited the ADP-ribosyl trans-
ferase activity of cholera toxin [21]. In this study, Daio used in the
B2F1 and GFP-B2F1 models may wash out B2F1 with an increase in
bowel movements, because the mice treated with Daio had a lot of
diarrhea (data not shown). Some components from Daio might also
inhibit the colonization of the mouse colon by B2F1. This is the
effect that we expected to observe, because we assumed that the
pathogen could be cleared out from the gut. In addition, there are
still many active substances in Daio, for example, rhein, which has
Fig. 3. Combination treatment with AZM and Daio in the E32511 model. (A) A single dose of 200 mg/g AZM 6 h after infection, combined with 300 mg/g Daio (twice) 2 h and 24 h
after infection, but not 200 mg/g AZM alone 6 h after infection or 200 mg/g AZM 6 h after infection combined with 300 mg/g Daio (once) 2 h after infection, had a statistically
signiﬁcant effect on the survival curve 200 mg/g AZM 6 h after infection combined with Daio (twice) vs. untreated, p ¼ 0.009; 200 mg/g AZM only and 200 mg/g AZM 6 h after
infection combined with Daio (once) vs. untreated, p > 0.05. (B) Viable E32511 decreased signiﬁcantly in feces of E32511-infected mice treated with 200 mg/g AZM 6 h after infection
combined with 300 mg/g Daio (twice) 2 h and 24 h after compared with treatment with 200 mg/g AZM alone 6 h after infection (day 1 AZM combination Daio vs. AZM alone,
p ¼ 0.022; day 2 AZM combination Daio vs. AZM alone, p ¼ 0.001 and day 3 AZM combination Daio vs. AZM alone, p < 0.0001). Student’s t test, *p < 0.05; **p < 0.001.
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gram-positive bacteria and acid-fast bacteria, but has weak activity
against E. coli [22]. In accordance with our in vitro experiments, we
checked the MIC of Daio against E32511 and showed that this
medicine did not have any antibacterial activity (data not shown).
Furthermore, it has been reported that Daio has an anti-
inﬂammatory effect by inhibiting the metabolism of arachidonic
acid to prostaglandins E2 and F2 and thromboxane in vitro [23,24].
Our results showed that the administration of a single dose of
200 mg/g AZM 6 h after inoculation with the bacteria was not
effective in improving the survival rates of infected mice, but when
combined with Daio once a day for two days, the survival rates
improved and the number of viable bacteria in the feces signiﬁ-
cantly decreased. Antibiotic use during E. coli O157:H7 infections
has been reported to be associated with a higher rate of subsequent
HUS and should be avoided [25]. However, in the biggest outbreak
of EHEC O104:H4 in Germany, treatment with AZM was associated
with a lower frequency of long-term STEC carrier status [26]. We
then investigated the effectiveness of Daio treatment alone using
the GFP-B2F1model, infectedwith 104 CFU of GFP-B2F1. Our results
showed that Daio effectively promoted survival after EHEC infec-
tion compared with the untreated mice. The number of bacteria
that colonized the colon and small intestine decreased 3 and 5 days
after treatment demonstrating that Daio prevents the colonization
of bacteria in the colon and small intestine.
It was very difﬁcult to completely eliminate gram-negative
bacteria like E. coli E32511 in the mouse feces by treatment with
AZM only. However, we showed that a combination of AZM and
Daio could reduce E32511 in the mouse feces. Furthermore, only
Daio prevented the colonization of the mouse colon by B2F1. These
results, however, merit further and thorough investigations.Acknowledgments
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